skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

1000 Total results for product and free and sample content found

Datamonitor Healthcare

Immuno-Oncology - A Deep Dive into Non-Small Cell Lung Cancer

By Andrew Benson 23 Jul 2018

NSCLC is one of the hottest areas in Oncology today. Watch now "The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)", a webinar from Informa Pharma Intelligence. Our panel of experts provided their insights into the clinical landscape and commercial implications of NSCLC.

Pink Sheet

Biogen BeNeLuxA Spinraza Talks Collaborative And Constructive But Not Without Challenges

By Francesca Bruce 23 Jul 2018

Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.

Topic Business strategies

Pink Sheet

Who's Promised What: A Guide To Pharma Drug Pricing Pledges

By Mandy Jackson 23 Jul 2018

Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions? 

Topic Strategy

Scrip

Mehta Analysis: China, A Populist Pharma Power

By Viren Mehta 20 Jul 2018

With money pouring into biopharma in China, and regulatory reforms favoring market growth and R&D speed, western firms should watch their backs, warns Viren Mehta, founding partner of Mehta Partners LLC.

Topic Policy and regulation

Scrip

Pharma's 2018 Deal-Making Story, So Far

By Jo Shorthouse 20 Jul 2018

Pharma has been busy making deals this year, while the political winds of change swirl overhead, as our infographic shows. Companies both big and small have been merging to carve out therapeutic niches, return value to shareholders, and position themselves for the next wave of innovation and change.

Topic Business strategies

Scrip

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

By Emily Hayes 18 Jul 2018

The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.

Topic Obesity Clinical trials

Scrip

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint

By Jessica Merrill 18 Jul 2018

J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly. 

Topic Policy and regulation

Medtech Insight

Open Payments: Zimmer, Medtronic Top List Of Spenders

By Elizabeth Orr 17 Jul 2018

Major medical device companies paid almost $1bn in consulting fees, royalties, research costs and other expenses to physicians in 2017, the most recent data release from the US Open Payments database shows. Zimmer Biomet reported the highest spending on general physician payments, while Roche and Medtronic topped the list of research spending.

Topic Clinical trials

Medtech Insight

Compliance Corner: Follow These 4 Tips From FDA's Maisel For A Better Pre-Market Experience

By Shawn M. Schmitt 17 Jul 2018

Bill Maisel – the director of the Office of Device Evaluation within US FDA's Center for Devices and Radiological Health (among other titles) – says there are four things device-makers should do to make sure they succeed during the product-review process.

Topic Business strategies

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: